Constance A. Benson
Experienced in Toxoplasmosis

Dr. Constance A. Benson

Infectious Disease
200 W Arbor Dr, Mc 8201, 
San Diego, CA 
42 Years of Experience
Experienced in Toxoplasmosis
200 W Arbor Dr, Mc 8201, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Constance Benson is an Infectious Disease provider in San Diego, California. Dr. Benson has been practicing medicine for over 42 years and is rated as an Experienced provider by MediFind in the treatment of Toxoplasmosis. Her top areas of expertise are HIV/AIDS, Syphilis, Toxocariasis, and Hepatitis.

Her clinical research consists of co-authoring 116 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Toxoplasmosis.

Specialties
Infectious Disease
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

200 W Arbor Dr, Mc 8201, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Digital Health Feedback System (DHFS) for Anti-Retroviral Therapy Medication Adherence and Transitions of Care Support During Hospital Admissions for Persons Living With HIV
Digital Health Feedback System (DHFS) for Anti-Retroviral Therapy Medication Adherence and Transitions of Care Support During Hospital Admissions for Persons Living With HIV
Enrollment Status: Completed
Publish Date: December 16, 2024
Intervention Type: Device
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
A Prospective Single Arm Open Label Intervention Study Using the DHFS With HIV Infected Participants Initiating or Continuing HIV Treatment
A Prospective Single Arm Open Label Intervention Study Using the DHFS With HIV Infected Participants Initiating or Continuing HIV Treatment
Enrollment Status: Unknown
Publish Date: December 23, 2022
Intervention Type: Device
Study Phase: Phase 4
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Enrollment Status: Completed
Publish Date: October 14, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Enrollment Status: Terminated
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

117 Total Publications

Seroprevalence and Risk Factors for Toxoplasma gondii Infection in People Living with HIV: A Cross-Sectional Study from Maputo Central Hospital, Mozambique.
Seroprevalence and Risk Factors for Toxoplasma gondii Infection in People Living with HIV: A Cross-Sectional Study from Maputo Central Hospital, Mozambique.
Journal: Research and reports in tropical medicine
Published: February 02, 2025
Similar Doctors
Experienced in Toxoplasmosis
Dr. Fadi A. Haddad
Infectious Disease
Experienced in Toxoplasmosis
Dr. Fadi A. Haddad
Infectious Disease

Emergency And Acute Care Medical Corporation

5555 Grossmont Ctr Dr, 
La Mesa, CA 
 (9.4 miles away)
619-740-6000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fadi Haddad is an Infectious Disease provider in La Mesa, California. Dr. Haddad is rated as a Distinguished provider by MediFind in the treatment of Toxoplasmosis. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Osteomyelitis, and Strep Throat.

Experienced in Toxoplasmosis
Dr. Ajay R. Bharti
Infectious Disease
Experienced in Toxoplasmosis
Dr. Ajay R. Bharti
Infectious Disease

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajay Bharti is an Infectious Disease provider in San Diego, California. Dr. Bharti is rated as an Advanced provider by MediFind in the treatment of Toxoplasmosis. His top areas of expertise are Osteomyelitis, Coccidioidomycosis, Osteomyelitis in Children, and Infectious Arthritis.

Scott L. Letendre
Experienced in Toxoplasmosis
Dr. Scott L. Letendre
Infectious Disease
Experienced in Toxoplasmosis
Dr. Scott L. Letendre
Infectious Disease

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (0.1 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances

Scott Letendre is an Infectious Disease provider in San Diego, California. Dr. Letendre is rated as a Distinguished provider by MediFind in the treatment of Toxoplasmosis. His top areas of expertise are HIV/AIDS, AIDS Dementia Complex, Myelitis, AIDS Dysmorphic Syndrome, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Benson's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile